APOE and cancer: In addition, epidemiology studies will continue to determine whether genetic risk factors for neurodegenerative diseases, for example, variations in apolipoprotein E (APOE) (Ahles et al, 2003; Mandelblatt et al, 2018) or COMT, can predict risks of developing chemobrain in cancer survivors.